



Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016



Condensed Interim Consolidated Statements of Financial Position

(unaudited)

As at: <i>In thousands of US dollars</i>	Notes	January 31, 2017	April 30, 2016
Assets			
Current assets:			
Cash		\$ 4,945	\$ 28,109
Prepaid expenses and deposits		610	743
Investment tax credit receivable		98	51
Other assets		135	42
Clinical supplies		3,312	1,849
Due from related parties		187	5,687
Total current assets		9,287	36,481
Non-current assets:			
Property and equipment		667	830
Intangible assets		2,034	1,753
Prepaid expenses and deposits		445	467
Deferred financing costs		38	38
Clinical supplies		1,040	528
Total non-current assets		4,224	3,616
Total assets		\$ 13,511	\$ 40,097
Liabilities			
Current liabilities:			
Trade and other payables		\$ 5,435	\$ 4,942
Accrued interest		957	1,443
Warrant liability	7 (d)	8,690	8,225
Debt	5	49,708	-
Total current liabilities		64,790	14,610
Non-current liabilities:			
Debt	5	-	47,716
Royalty preferred shares	6	39,200	34,200
Total liabilities		103,990	96,526
Shareholders' equity (deficit):			
Share capital	7 (a)	172,641	172,346
Contributed surplus		38,966	38,671
Warrants	7 (e)	440	440
Deficit		(302,526)	(267,886)
Total shareholders' deficit		(90,479)	(56,429)
Total liabilities and shareholders' equity		\$ 13,511	\$ 40,097
Future operations (note 3)			
Commitments (note 9)			

Signed on behalf of the Board:

Signed: "Dr. Eldon Smith" Director

Signed: "Kenneth Zuerblis" Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Comprehensive Loss
For the three and nine months ended January 31
(unaudited)

<i>In thousands of US dollars</i>	Notes	Three months ended January 31,		Nine months ended January 31,	
		2017	2016	2017	2016
Expenses:					
Research and development, net of recoveries	8	\$ 8,699	\$ 3,946	\$ 21,225	\$ 9,384
Investment tax credits		(17)	(7)	(48)	(34)
Net research and development		8,682	3,939	21,177	9,350
General and administrative	8	979	810	3,198	3,035
		9,661	4,749	24,375	12,385
Finance costs (income):					
Loss (gain) on change in fair value of warrant liability	7 (d)	46	(1,756)	465	(11,681)
Loss on change in fair value of royalty preferred shares	6	200	4,800	5,000	7,300
Interest and accretion		1,801	1,475	5,231	4,645
Foreign exchange loss (gain)		1,271	(396)	(493)	(2,608)
Net finance costs (income)		3,318	4,123	10,203	(2,344)
Loss before income taxes		12,979	8,872	34,578	10,041
Income taxes:					
Current tax expense (recovery)		16	3	62	(5)
Net and total comprehensive loss		\$ 12,995	\$ 8,875	\$ 34,640	\$ 10,036
Net loss per share (note 7 (f))					
Basic and diluted		\$ 0.12	\$ 0.08	\$ 0.33	\$ 0.10

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Changes in Shareholders' Deficit
For the nine months ended January 31
(unaudited)

<i>In thousands of US dollars</i>	Share Capital	Contributed Surplus	Warrants	Deficit	Total Shareholders' Deficit
Balance, April 30, 2015	\$ 136,499	\$ 37,945	\$ -	\$ (248,171)	\$ (73,727)
Common shares issued in connection with private placement 7 (a)	36,925	-	-	-	36,925
Common shares issued in connection with warrant exercises	171	-	-	-	171
Common shares issued in connection with stock option and long term incentive plans	392	(484)	-	-	(92)
Share issue costs	(1,641)	-	-	-	(1,641)
Warrants issued in connection with private placement 7 (e)	-	-	440	-	440
Share-based payment transactions	-	871	-	-	871
Net and total comprehensive loss	-	-	-	(10,036)	(10,036)
Balance, January 31, 2016	\$ 172,346	\$ 38,332	\$ 440	\$ (258,207)	\$ (47,089)
Balance, April 30, 2016	\$ 172,346	\$ 38,671	\$ 440	\$ (267,886)	\$ (56,429)
Common shares issued in connection with stock option and long term incentive plans	295	(539)	-	-	(244)
Share-based payment transactions	-	834	-	-	834
Net and total comprehensive loss	-	-	-	(34,640)	(34,640)
Balance, January 31, 2017	\$ 172,641	\$ 38,966	\$ 440	\$ (302,526)	\$ (90,479)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.



Condensed Interim Consolidated Statements of Cash Flows

For the nine months ended January 31

(unaudited)

<i>In thousands of US dollars</i>	2017	2016
Cash provided by (used in):		
Cash flows used in operating activities:		
Net loss	\$ (34,640)	\$ (10,036)
Items not involving cash:		
Equity-settled share-based payment transactions	834	871
Depreciation and amortization	297	208
Change in fair value of warrant liability	465	(11,681)
Change in fair value of royalty preferred shares	5,000	7,300
Unrealized foreign exchange	(1,757)	(6,685)
Interest and accretion	5,231	4,645
Income taxes	62	(5)
Changes in non-cash working capital:		
Investment tax credit receivable	(47)	(29)
Clinical supplies	(1,975)	(2,146)
Prepaid expenses and deposits	133	(782)
Long term prepaid expenses and deposits	22	(169)
Other assets	(113)	8
Due from related parties	5,500	(3,201)
Trade and other payables	1,624	4,070
	(19,364)	(17,632)
Interest received	131	220
Income tax paid	(87)	(26)
Net cash used in operating activities	(19,320)	(17,438)
Cash flows (used in) generated from financing activities:		
Proceeds from the issuance of common shares and warrants	-	38,810
Share issuance costs	-	(1,190)
Deferred financing costs	-	(38)
Proceeds from exercise of stock options	26	50
Proceeds from exercise of warrants	-	102
Restricted stock unit costs	(271)	(143)
Interest and fees paid	(2,079)	(2,394)
Changes in non-cash financing working capital	-	(11)
Net cash (used in) generated from financing activities	(2,324)	35,186
Cash flows used in investing activities:		
Property and equipment additions (net)	(21)	(20)
Intangible asset additions (net)	(393)	(441)
Changes in non-cash investing working capital	(100)	(30)
Net cash used in investing activities	(514)	(491)
Effect of foreign currency translation on cash	(1,006)	(3,541)
(Decrease) increase in cash	(23,164)	13,716
Cash, beginning of period	28,109	16,211
Cash, end of period	\$ 4,945	\$ 29,927

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

1. General information

Resverlogix Corp. (the “Company”) is a company domiciled in Canada. The annual consolidated financial statements comprise the Company and its wholly-owned subsidiary Resverlogix Inc. (together referred to as the “Group”). Resverlogix Corp. is incorporated under the laws of Alberta. Resverlogix Inc. is incorporated under the laws of Delaware. The Company’s head office is located at Suite 300, 4820 Richard Road S.W., Calgary, Alberta, T3E 6L1. The registered and records office is located at Suite 600, 815 - 8th Avenue S.W., Calgary, Alberta, T2P 3P2.

Resverlogix Corp. is a clinical stage biotechnology company developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (“BET”) inhibitor for the potential treatment of patients with high-risk cardiovascular disease (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases. The Company is considered to be in the development stage, as most of its efforts have been devoted to research and development and it has not earned any revenue to date.

2. Basis of preparation

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with IAS 34 – *Interim Financial Reporting*. These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors on March 14, 2017.

Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with IFRS, has been omitted or condensed. These condensed interim consolidated financial statements do not include all disclosures required under IFRS and, accordingly, should be read in conjunction with the annual financial statements for the year ended April 30, 2016 and the notes thereto prepared in accordance with International Financial Reporting Standards (“IFRS”) as prescribed by the International Accounting Standards Board (“IASB”).

(b) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis except for the revaluation of the liability classified warrants and liability classified royalty preferred shares, which are measured at fair value each reporting period. Long-term debt is measured initially at fair value and subsequently at amortized cost. Historical cost is based on the fair value of the consideration given in exchange for assets recorded on the date of the transaction.

(c) Functional and presentation currency

The functional currency of all entities within the Group is the US dollar, which is also the presentation currency. All financial information presented in dollars has been rounded to the nearest thousand except for per share amounts.

(d) Use of estimates and judgment

The preparation of the condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the amounts reported in these condensed interim consolidated financial statements and notes. Accordingly, actual results may differ from estimated amounts as future confirming events occur. Significant estimates and judgment used in the preparation of the condensed interim consolidated financial statements remain unchanged from those described in the Group’s consolidated financial statements for the year ended April 30, 2016.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

3. Future operations

The success of the Company is dependent on the continuation of its research and development activities, progressing the core technologies through clinical trials to commercialization and its ability to finance its cash requirements.

It is not possible to predict the outcome of future research and development programs, the Company's ability to fund these programs in the future, or the commercialization of products by the Company.

The accompanying condensed interim consolidated financial statements have been prepared pursuant to International Financial Reporting Standards applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. The Company has incurred significant losses to date, and with no assumption of revenues, is dependent on its ability to raise additional financial capital by continuing to demonstrate the successful progression of its research and development activities if it is to remain as a going concern.

As at January 31, 2017, the Company had \$4.9 million of cash and was committed to pay \$5.4 million of trade and other payables, \$1 million of accrued interest, \$5.6 million for research and development and \$0.8 million of lease obligations over the next twelve months as described further in Note 9. In addition, expenditures over the next twelve months under cancellable agreements with contract research organizations and central laboratories conducting the BETonMACE and other trials were estimated to total approximately \$17-22 million. The Company's CAD\$68.8 million (US\$52.8 million) loan is repayable upon maturity on August 28, 2017, and the Company is committed to pay CAD\$2.9 million of interest on August 28, 2017.

Zenith Capital Corp. ("Zenith") agreed to pay the Company for its proportionate share of operating lease payments and operating costs for office and laboratory premises of an estimated \$0.2 million and \$0.1 million, respectively, for the next twelve months.

The Company's cash as at January 31, 2017 will be insufficient to fund the Company's contractual commitments for the next year or the Company's planned business operations over the next year based on anticipated patient enrollment for BETonMACE. The Company will have to raise additional capital.

The Company continues to engage in discussions regarding extending its loan, however there is no assurance that the loan will be extended. Regardless of loan extension, the Company will be seeking additional capital for existing and expanded indications. Subsequent to January 31, 2017, the Company entered into an agreement with an agent regarding the replacement of the Company's existing loan. The Company also intends to complete an equity private placement within the next month. The Company is examining both non-dilutive and dilutive arrangements, with a preference for non-dilutive alternatives, in the following priority: co-development, licensing, rights (on indications or potential follow-on compounds, for instance) or other partnering arrangements, private placements and/or public offerings (equity and/or debt); therefore, the Company frequently engages in such discussions.

If the Company is not able to raise capital, the Company will have to reduce its cash requirements by eliminating or deferring spending on research, development and corporate activities.

These conditions result in a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern.

The Company will also require additional capital to fund research, development and corporate activities beyond the next year. The Company will continue to explore alternatives to generate additional cash including raising additional equity and/or debt and/or partnering; however, there is no assurance that these initiatives will be successful.

These financial statements do not include any adjustments to the amounts and classifications of assets and liabilities, and the reported expenses that might be necessary should the Company be unable to continue as a going concern.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

4. Significant accounting policies

The condensed interim consolidated financial statements should be read in conjunction with the Company's annual consolidated financial statements for the year ended April 30, 2016 prepared in accordance with IFRS applicable to those annual consolidated financial statements. Except as disclosed below, the same accounting policies, presentation and methods of computation have been followed in these condensed interim consolidated financial statements as were applied in the Company's consolidated financial statements for the year ended April 30, 2016.

New standards and interpretations adopted

We have adopted the following new standards and amendments to standards, with a date of initial application of May 1, 2016:

Annual Improvements

The IASB issued narrow-scope amendments to a total of four standards as part of its annual improvements released on September 24, 2014 to be implemented for periods beginning on or after January 1, 2016. These included a clarification on IAS 34 *Interim Financial Reporting* that the disclosures required under the standard are to be included within the notes to the financial statements, or to be incorporated there by cross-reference, and is to be applied retrospectively. The amendments did not have a material impact on our financial statements.

Disclosure Initiative

On December 18, 2014, the IASB issued amendments to IAS 1 *Presentation of Financial Statements* to be implemented for periods beginning on or after January 1, 2016. The amendments made changes to clarify the objectives of disaggregation, materiality, and the ordering of notes in order to ensure that entities are able to use judgement when reporting financial results. The amendments did not have a material impact on our financial statements.

Share-based Payment

On June 20, 2016, the IASB issued amendments to IAS 2 *Share-based Payment* to be implemented prospectively for periods beginning on or after January 1, 2018. The Company early adopted the amendments. The amendments made changes to the classification of share-based payment transactions with net settlement features. The amendments did not have a material impact on our financial statements.

5. Debt

	January 31, 2017	April 30, 2016
CAD\$68.8 million, 4.0560% due August 28, 2017	\$ 52,804	\$ 54,826
Discount on debt, net of accretion	(2,118)	(4,869)
Unamortized transaction costs, net of accretion	(978)	(2,241)
Carrying value of debt	\$ 49,708	\$ 47,716

On August 27, 2012, the Company entered into a CAD\$25.0 million Loan Agreement with Citibank, N.A. ("Citibank"). The Company received the CAD\$25.0 million on August 30, 2012. On March 8, 2013, the Company entered into a Loan Amendment with Citibank to increase the loan from CAD\$25.0 million to CAD\$38.8 million, all other existing terms and conditions remained unchanged. The Company received the additional CAD\$13.8 million upon closing of the loan on March 11, 2013. On July 3, 2014, the Company entered into a Second Loan Amendment with Citibank which provided for the existing loan granted to the Company by Citibank to be increased by CAD\$30.0 million to CAD\$68.8 million. All other existing terms and conditions remained unchanged. The Company received the additional CAD\$30.0 million upon closing on August 15, 2014.

The entire loan is repayable upon maturity on August 28, 2017 and may be repaid prior to maturity in whole or in part without penalty. The Company is in discussions regarding extending the loan. Effective August 27, 2016, the annual interest rate was reset from 3.7643% to 4.0560%. Interest on the loan is payable annually in arrears and the interest rate is reset annually to a rate equal to Canadian one-year LIBOR swap rate plus 3.14%. The loan is secured by an irrevocable CAD\$68.8 million Standby

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

5. Debt (continued)

Letter of Credit (the "Letter of Credit") in favour of Citibank arranged by Eastern Capital Limited ("Eastern"), which will be maintained until maturity of the loan.

In connection with the irrevocable Standby Letter of Credit, on August 27, 2012 the Company issued 1,320,000 share purchase warrants exercisable at a price of CAD\$1.58 (subsequently adjusted to CAD\$1.44) for a period of five years to Eastern, and on March 8, 2013 the Company issued an additional 728,640 share purchase warrants exercisable at a price of CAD\$2.38 (subsequently adjusted to CAD\$2.16) for a period of five years to Eastern. In connection with the Second Loan Amendment, the Company issued 5,000,000 share purchase warrants exercisable at a price of CAD\$0.75 for a period of five years to Eastern. The Company will pay a guarantee fee to Eastern in the amount of 0.03% per annum on the average daily aggregate principal amount of the issued and undrawn Letter of Credit, and pledged its issued letters patent to Eastern.

The Company determined the fair value of the initial CAD\$25.0 million long-term debt to be \$18.6 million which is net of a \$6.7 million debt discount, and determined the fair value of the subsequent CAD\$13.8 million long-term debt to be \$10.2 million which is net of a \$3.3 million debt discount. The further CAD\$30.0 million was determined to have a fair value of \$22.6 million which is net of a \$4.9 million debt discount. Management's estimate of the market interest rate for the debt was 12%, and attributed the loan's lower interest rate to the Letter of Credit arranged by Eastern.

The Company used significant judgment in determining whether Eastern was acting in the capacity of a shareholder or a provider of service. Based on discussions with Eastern, consideration of the terms of the arrangements between Eastern, Citibank and Resverlogix whereby Eastern provided its assets as collateral to Citibank in connection with a loan from Citibank to Resverlogix, and the risks and rewards associated therewith, management determined that Eastern was acting in the capacity of a shareholder in arranging the Letter of Credit; therefore, the debt discounts were recognized as contributed surplus. The combined debt discount is to be amortized over the term of the long-term debt. The determination of the fair value of the long term debt required management to use judgment, including management's estimate of a market interest rate for the debt of 12%. In addition, the Company determined the fair value of the 1,320,000, 728,640 and 5,000,000 warrants to be \$1.5 million, \$1.4 million and \$3.2 million, respectively. The Company recorded the warrants as a liability (see Note 7 (d)) with an off-setting reduction to the carrying amount of the debt to be amortized as interest and accretion expense over the term of the long-term debt. Management's estimate of the market interest rate for the debt as at January 31, 2017 was unchanged at 12% and, as such, the carrying value of the long-term debt approximates the fair value.

6. Royalty preferred shares

(i) Authorized:

Unlimited number of preferred shares issuable in series with rights as determined by the Board of Directors at the time of issue.

(ii) Issued and outstanding:

Preferred shares	Number of shares	Amount
Balance, April 30, 2015	75,202,620	\$ 27,800
Revaluation of royalty preferred shares	-	6,400
Balance, April 30, 2016	75,202,620	34,200
Revaluation of royalty preferred shares	-	5,000
Balance, January 31, 2017	75,202,620	\$ 39,200

As at January 31, 2017, the Company had 75,202,620 royalty preferred shares outstanding, all of which were held by Zenith. On July 2, 2015, the Company's articles were amended to make certain changes to the dividend entitlement of holders of royalty preferred shares. As a result of the amendment, the dividend amount in a prescribed dividend payment period may not exceed the aggregate of all amounts received by Resverlogix or its affiliates in respect of and including Net Revenue in such period. On December 20, 2016, the Company's articles were amended to make certain additional changes to the dividend entitlement of holders of royalty preferred shares. The amendments provided that the holder of royalty preferred shares is entitled to a dividend, calculated based on a percentage of net revenue earned from the sale of licensing of any pharmaceutical product in

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

6. Royalty preferred shares (continued)

(ii) Issued and outstanding: (continued)

which Resverlogix holds an intellectual property right, and removed the requirement that the pharmaceutical product elevate plasma levels of certain lipoprotein associated with a decreased risk of atherosclerosis and coronary heart disease.

The holder of the royalty preferred shares is entitled to dividends in the amount of 6-12% of Resverlogix's Net Revenue, if any. Net Revenue is defined as the aggregate of the following amounts: (i) amounts received by the Company or its affiliates from any person who is not the Company or its affiliate (a "third party") in consideration for granting a license or other rights to the third party which entitle the third party to research, develop, make, manufacture, modify, administer, offer to sell, sell or distribute one or more of Resverlogix's products and/or intellectual property rights or amounts received under the terms of such license or other right that are granted to the third party; (ii) the gross consideration received from a third party by the Company, any licensee or their respective affiliates from the sale of any product (other than consideration received by the Company, any licensee or their respective affiliates from a licensee of such product or its affiliate); less (A) credits or allowances, if any, actually granted; (B) discounts actually allowed; (C) freight, postage, and insurance charges and additional special packaging charges; (D) customs duties, and excise sales taxes, duties or other taxes imposed upon and paid with respect to such sales (excluding what is commonly known as income taxes); (E) rebates and chargebacks or retroactive price reductions made to federal, state or local governments (or their agencies), or any third party payor, administrator or contractor, including managed health organizations; and (F) commissions related to import, distribution or promotion of any Product paid to third parties (specifically excluding any commissions paid to sales personnel, sales representatives and sales agents who are employees or consultants of, or members of a contract sales force engaged by or on behalf of the Company, any licensee or their respective affiliates); (iii) amounts received from a third party by the Company or its affiliates in consideration for the sale of any intellectual property right. The holder of the preferred shares does not have any claim on the Company's residual net assets.

As these preferred shares contain a non-discretionary royalty dividend they represent a contractual obligation to deliver cash.

IFRS requires that the substance of the instrument takes precedence over the legal form and thus the preferred shares have been classified as a financial liability. The liability is required to be re-measured to its fair value at each reporting period end with changes in fair value recognized in the statement of comprehensive loss (income).

For fair value measurement purposes, the royalty preferred shares liability has been categorized within level 3 of the fair value measurement hierarchy. The fair value of the royalty preferred shares is based on management's judgments, estimates and assumptions which include significant unobservable inputs including the timing and amounts of the Company's discounted risk adjusted future net cash flows. The estimate incorporates the following assumptions: a cumulative probability rate of generating forecasted future cash flows of 35% as at January 31, 2017 (April 30, 2016 - 35%) reflecting in each case, among other factors, the Company's clinical results and communication with regulatory bodies; a discount rate of 23.8% as at January 31, 2017 (April 30, 2016 - 23.5%); commencement of revenue beginning between 2021 and 2023 (based on clinical development paths across various jurisdictions) as at January 31, 2017 (April 30, 2016 - between 2021 and 2023); apabetalone market share percentages; and product pricing.

As at January 31, 2017, management updated the estimated fair value to reflect the length of time from January 31, 2017 to future cash flows based on the estimated timing and commencement of revenue and reduced the discount rate due to a decrease in the risk-free rate of return.

The fair value of the royalty preferred shares is subject to significant volatility. Small changes in the aforementioned assumptions may have a significant impact on the fair value of the royalty preferred shares. Holding all other assumptions constant, a 1% increase in the discount rate would result in a \$3.6 million decrease in the fair value of the royalty preferred shares. Assuming commencement of revenue one year later would result in an \$6.2 million decrease in the fair value of the royalty preferred shares.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit)

(a) Common shares

(i) Authorized:

Unlimited number of common shares.

(ii) Issued and outstanding:

Common shares	Number of shares	Amount
Balance, April 30, 2015	86,106,938	\$ 136,499
Issued in connection with private placement	18,870,000	36,925
Issued in connection with warrant exercises	60,000	171
Issued in connection with stock option plan	52,333	97
Issued in connection with long term incentive plan	106,145	295
Share issue cost	-	(1,641)
Balance, April 30, 2016	105,195,416	172,346
Issued in connection with long term incentive plan	262,361	243
Issued in connection with stock option plan	32,767	52
Balance, January 31, 2017	105,490,544	\$ 172,641

Private placements

On July 8, 2015, the Company formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") and closed a license of apabetalone for China, Hong Kong, Taiwan and Macau (the "Territories"), for all indications with Hepalink. On July 20, 2015, the Company closed the private placement. Under the terms of the transaction, Hepalink subscribed for 13,270,000 Resverlogix common shares and 1,000,000 common share purchase warrants for gross proceeds of \$27.3 million (CAD\$35.4 million), or CAD\$2.67 per unit. After giving effect to the transaction, Hepalink held approximately 12.63% of Resverlogix's common shares. The common shares and warrants issued to Hepalink are subject to a three year lock-up period. In addition, Eastern purchased 5,600,000 common shares and 422,005 common share purchase warrants for gross proceeds of \$11.5 million (CAD\$15.0 million), or CAD\$2.67 per unit. After giving effect to the transaction, Eastern held approximately 19.57% of Resverlogix's common shares. The 1,422,005 warrants issued on July 20, 2015 have an exercise price of CAD\$2.67 and expire on July 20, 2020. These warrants were valued at \$1.9 million using the Black-Scholes option pricing model; the residual \$36.9 million of proceeds was assigned to share capital.

The license between Resverlogix and Hepalink provides for certain milestone payments based on net sales of apabetalone in the licensed territories. The annual sales milestones range from 500 million renminbi ("RMB") to 10 billion RMB (US\$74 million to US\$1.5 billion), with Resverlogix being eligible to receive sales-based milestone payments from Hepalink ranging from US\$5 million to US\$90 million. In addition, Hepalink shall pay a royalty of 6% of annual net sales of apabetalone in the licensed territories. Hepalink will be responsible for all clinical and development costs in the Territories, including a patient population that is expected to be included in the Company's planned Phase 3 BETonMACE trial. The Company is contractually obligated to pay a fee to the financial advisor involved with the transaction equal to 3.5% on the first \$10.0 million of payments, if any, received from Hepalink pursuant to the license, and 2.5% on amounts above \$10.0 million, up to a maximum of \$1.0 million of fees. As at January 31, 2017, these potential payments do not satisfy the criteria for recognition as a liability.

Base shelf prospectus

On October 5, 2015, the Company obtained a receipt for a final short-form base shelf prospectus filed on October 1, 2015 with the securities commissions in each of the provinces of Canada except Quebec. Subject to securities regulations, the short-form base shelf prospectus (the "base shelf prospectus") allows the Company to make offerings of common shares, preferred shares, debt securities, warrants, units, or any combination of such securities up to an aggregate offering price of CAD\$125 million during the 25 month period that the base shelf prospectus remains effective.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(a) Common shares (continued)

Share issue costs (recovery)

During the nine months ended January 31, 2017, the Company recognized total share issue costs of nil (2016 – \$1.6 million, including \$0.4 million associated with warrants issued to the financial advisor involved with the transaction, as described in Note 7 (e)).

(b) Stock options

The Company's amended stock option plan has been approved as a rolling 10% plan that allows for reservation of a number of common shares under the plan equal to 10% of the Company's issued and outstanding common shares on an undiluted basis.

Additionally, the plan is a reloading plan, which allows for the number of common shares reserved for issuance related to the options under the plan to automatically become eligible to be reallocated pursuant to stock option based grants upon option expiry, cancellation or exercise. The Company may grant options to its directors, officers, employees and consultants.

The majority of options fully vest over a period of between zero and three years and have terms of between three and five years. Certain stock options have performance conditions which must be satisfied in order for the options to vest. The options are settled by way of the issuance of equity instruments of the Company ("equity-settled").

	Number of options	Weighted average exercise price (CAD)
Outstanding, April 30, 2015	3,771,936	\$ 1.82
Granted	620,100	1.93
Exercised	(52,333)	1.21
Expired	(444,902)	2.80
Forfeited	(16,568)	1.28
Outstanding, April 30, 2016	3,878,233	1.74
Granted	843,800	1.41
Exercised	(32,767)	1.08
Expired	(1,215,368)	1.46
Forfeited	(12,499)	0.99
Outstanding, January 31, 2017	3,461,399	\$ 1.77

The following table summarizes information about the options outstanding and exercisable at January 31, 2017.

Range of Exercise Prices (CAD)	Number Outstanding	Weighted Average Remaining Life (years)	Weighted Average Exercise Price (CAD)	Number Exercisable
\$0.65 - \$0.75	457,100	2.34	\$ 0.70	453,767
\$1.04 - \$1.82	1,979,699	2.95	1.41	709,199
\$2.26 - \$2.86	612,000	2.08	2.74	489,472
\$3.19 - \$3.27	412,600	1.30	3.24	412,600
	3,461,399	2.52	\$ 1.77	2,065,038

The number of options exercisable at January 31, 2017 was 2,065,038 (2016 – 3,055,065) with a weighted average exercise price of CAD\$1.93 (2016 – CAD\$1.74).

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(b) Stock options (continued)

The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model. The following weighted average assumptions were used in arriving at the weighted average fair values of \$0.96 per option and \$1.53 per option associated with stock options granted during the nine months ended January 31, 2017 and 2016, respectively:

	2017	2016
Risk-free interest rate	0.8%	0.7%
Expected life	4.2 years	4.3 years
Expected volatility	162%	162%
Share price at grant date	CAD\$1.38	CAD\$2.14
Expected dividends	Nil	Nil

(c) Restricted stock units

The Company's long term incentive plan allows for the reservation of a number of common shares not to exceed 10% of the Company's issued and outstanding common shares on an undiluted basis less the number of common shares reserved under the Company's amended stock option plan. The Company may grant restricted stock units ("RSUs") to directors, officers, employees, and consultants.

During the three and nine months ended January 31, 2017, the Company granted nil and 405,000 RSUs, respectively (2016 – nil and 364,239 RSUs, respectively). The RSUs vest over a period of between one and three years. The weighted average fair value of the RSUs granted in the three and nine months ended January 31, 2017 was nil and \$0.98 per RSU, respectively (2016 – nil and \$1.79 per RSU, respectively). The Company estimates the fair value of RSUs based on the market price of the underlying stock on the date of grant.

On September 30, 2016 and December 21, 2016, the Company allowed the exercise of restricted stock units on a "net of tax" basis, whereby the number of shares issued was equal to the number determined net of the respective taxes attributable to the exercise; 424,718 RSUs were exercised on a net of tax basis, resulting in the issuance of 238,127 common shares.

On June 30, 2015, the Company allowed the exercise of restricted stock units on a "net of tax" basis, whereby the number of shares issued was equal to the number determined net of the respective taxes attributable to the exercise; 219,195 RSUs were exercised on a net of tax basis, resulting in the issuance or distribution of 4,779 common shares (129,231 common shares were distributed from the remaining 153,877 common shares that were issued in fiscal 2014 and held by a financial institution to satisfy further redemptions under the Company's long term incentive plan, thus these exercises did not result in an increase in the number of common shares issued).

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(c) Restricted stock units (continued)

	Number of restricted stock units	Weighted average grant date fair value (USD)
Outstanding, April 30, 2015	577,131	\$ 0.97
Granted	364,239	1.79
Exercised	(345,207)	1.27
Forfeited	(7,066)	1.53
Outstanding, April 30, 2016	589,097	1.30
Granted	405,000	0.98
Exercised	(448,952)	1.14
Forfeited	(10,966)	1.15
Outstanding, January 31, 2017	534,179	\$ 1.19

(d) Warrant liability

The following table summarizes the changes in liability classified common share purchase warrants outstanding.

	Number of warrants	Weighted average exercise price (CAD)	Liability amount
Outstanding, April 30, 2015	10,644,482	\$ 1.31	\$ 18,651
Issued in connection with private placement	1,422,005	2.67	1,885
Exercised	(60,000)	2.05	(70)
Revaluation of warrant liability	-	-	(12,241)
Outstanding, April 30, 2016	12,006,487	1.47	8,225
Expired	(3,006,250)	2.05	-
Revaluation of warrant liability	-	-	465
Outstanding, January 31, 2017	9,000,237	\$ 1.28	\$ 8,690

The following table summarizes information about the liability classified warrants outstanding and exercisable at January 31, 2017.

Exercise Price (CAD)	Number Outstanding	Weighted Average Remaining Life (years)	Weighted Average Exercise Price (CAD)
\$0.75	5,000,000	2.54	\$ 0.75
\$0.90	529,592	1.53	0.90
\$1.44	1,320,000	0.57	1.44
\$2.16	728,640	1.10	2.16
\$2.67	1,422,005	3.47	2.67
	9,000,237	2.22	\$ 1.28

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(d) Warrant liability (continued)

Under IFRS, the prescribed accounting treatment for warrants issued as part of an equity financing unit or as part of a debt financing, with an exercise price denominated in a foreign currency, is to treat these warrants as a liability measured at fair value with subsequent changes in fair value each reporting period accounted for through profit or loss. The fair value of these warrants is determined using the Black Scholes option pricing model. The fair value of the warrants is subject to significant volatility. Small changes in certain Black Scholes model inputs, including the market price of the Company's common shares and estimated volatility may have a significant impact on the fair value of the warrants. During the nine months ended January 31, 2017 the market price of the Company's common shares increased to CAD\$2.06 on January 31, 2017 from CAD\$1.45 on April 30, 2016, resulting in a revaluation loss.

The Company's warrants summarized above satisfy liability classification requirements and are exercisable at any time and thus the value of these warrants are presented as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in share capital along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment.

On August 15, 2014, the Company issued 5,000,000 common share purchase warrants to Eastern, and on July 20, 2015 the Company issued 1,422,005 common share purchase warrants (comprised of 1,000,000 to Hepalink and 422,005 to Eastern). Each warrant issued on August 15, 2014 is exercisable at a price of CAD\$0.75 for a period of five years, and each warrant issued on July 20, 2015 is exercisable at a price of CAD\$2.67 for a period of five years.

The Company used significant judgment in determining whether Eastern was acting in the capacity of a shareholder or a provider of service with respect to the issuance of 5,000,000 warrants. Based on discussions with Eastern, consideration of the terms of the arrangements between Eastern, Citibank and Resverlogix whereby Eastern provided its assets as collateral to Citibank in connection with a loan from Citibank to Resverlogix, and the risks and rewards associated therewith, management determined the warrants were issued to Eastern (when providing the Letter of Credit to support the loan) in their capacity as a shareholder and thus were not in scope of IFRS 2 - *Share-based payment* and should be accounted for under IAS 32 - *Financial instruments: presentation*. Thus, the common share purchase warrants have been recognized as a financial liability with the fair value of the common share purchase warrants being treated as a transaction cost.

During the nine months ended January 31, 2017, no warrants were granted. The weighted average fair value of the warrants granted during the nine months ended January 31, 2016 was \$1.33 per warrant, respectively, using the Black-Scholes option pricing model with the following weighted average assumptions:

	2016
Risk-free interest rate	0.6%
Expected life	5 years
Expected volatility	156%

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(e) Equity classified warrants

On July 20, 2015, the Company issued 331,750 warrants to the financial advisor involved with the private placement as described in Note 7 (a). These warrants are classified as an equity instrument and accounted for under IFRS 2 – *Share-Based Payments* as they are a form of compensation for services rendered. Due to the equity classification the warrants will not be revalued each reporting period. Each warrant issued is exercisable at a price of CAD\$2.67 for a period of five years. The weighted average fair value of the warrants granted during the nine months ended January 31, 2016 was \$1.33 per warrant, using the Black-Scholes option pricing model with the same weighted average assumptions outlined in Note 7 (d). During the nine months ended January 31, 2017, no warrants were granted.

The following table summarizes information about the equity classified warrants outstanding and exercisable at January 31, 2017.

Exercise Price (CAD)	Number Outstanding	Weighted Average Remaining Life (years)
\$2.67	331,750	3.47

(f) Per share amounts

The basic and diluted loss per share has been calculated based on the weighted average shares outstanding:

	January 31,		January 31,	
	2017	2016	2017	2016
Weighted average common shares outstanding - basic and diluted	105,456,052	105,118,859	105,302,739	99,594,637

The effect of any potential exercise of stock options, restricted stock units and warrants outstanding is excluded from the calculation of diluted loss per share in periods where the effect would be anti-dilutive.

8. Expenses by nature

Presentation of expenses is based on the function of each expense. The following details highlight certain components of the research and development and general and administrative expenses classified by nature. Remaining research and development and general and administrative expenses include personnel costs and expenses paid to third parties.

	Three months ended		Nine months ended	
	January 31,		January 31,	
	2017	2016	2017	2016
Included in research and development expenses:				
Share-based payment transaction costs	\$ 82	\$ 81	\$ 247	\$ 348
Amortization and depreciation	52	51	212	122
Included in general and administrative expenses:				
Share-based payment transaction costs	\$ 193	\$ 150	\$ 587	\$ 523
Amortization and depreciation	28	22	85	86

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended January 31, 2017 and 2016

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

9. Commitments

As at January 31, 2017, the Group is party to cancellable agreements with contract research organizations and central laboratories conducting the BETonMACE and other trials. Corresponding aggregate expenditures over the next twelve months were estimated to total approximately \$17-22 million (2016 – \$19-24 million).

As at January 31, 2017, the Group is committed to expenditures over the next twelve months of \$5.6 million (2016 – \$2.3 million) under various research and development contracts.

As at January 31, 2017, the Group is also committed to operating lease payments for office and laboratory premises as follows:

	2017	2016
Less than 1 year	\$ 776	\$ 792
Between 1 and 5 years	2,548	2,728
More than 5 years	740	1,134
	\$ 4,064	\$ 4,654

Zenith has agreed to pay the Company for its proportionate share of operating lease payments and operating costs for office and laboratory of an estimated \$0.2 million and \$0.1 million, respectively, for the next twelve months.